한글목차

세계의 당뇨병 치료제 및 진단 시장 규모는 2025년 1,349억 달러로 평가되었고, 2030년 말 2,415억 달러에 이를 것으로 예측되며, 2025-2030년 CAGR은 12.4%로 전망됩니다.

북미 시장은 2025년 546억 달러로 평가되었고, 2030년 말까지 990억 달러에 이를 것으로 예측되며, 2025-2030년 CAGR은 12.6%로 전망됩니다.

아시아태평양 시장은 2025년 316억 달러로 평가되었고, 2030년 말 609억 달러에 이를 것으로 예측되며, 2025-2030년 CAGR은 14%로 전망됩니다.

본 보고서에서는 세계의 당뇨병 치료제 및 진단 시장을 조사했으며, 시장 개요, 시장 영향인자 및 시장 기회 분석, 기술 동향, 법 규제 환경, 시장 규모 추이 및 예측, 각종 구분, 지역별 상세 분석, 주요 기업의 프로파일 등을 정리했습니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 개요
• 현재 시장 시나리오
• 부문 분석
• 기술 진보
• 결론

제2장 시장 개요

• 개요
• 당뇨병의 역학
• 지역 분포
• 성별 분포
• Porter's Five Forces 분석
• 거시경제 요인 분석
• 의료비 지출
• 보험 적용 범위 및 환불 정책
• 기술의 진보
• 미국 관세 시나리오

제3장 시장 역학

• 개요
• 시장 성장 촉진요인
• 당뇨병 유병률 증가
• 고령화 인구 증가
• 라이프 스타일 습관의 변화
• 시장 성장 억제요인
• 당뇨병 치료의 고비용
• 중저소득국에서 의료 액세스의 제한
• 시장 기회
• 원격 감시를 위한 AI, IoT, 웨어러블 통합
• 정부의 자금 원조 및 대처
• 관민 파트너십 및 산업계의 제휴 확대
• 시장의 과제
• 데이터 프라이버시 및 사이버 보안의 위험
• 숙련된 전문가의 부족

제4장 규제 상황

• 규제 프레임워크
• 미국
• 유럽
• 기타 지역

제5장 신기술 및 개발

• 신흥 기술
• 차세대 인슐린 전달 시스템
• 멀티 GLP 효능제
• 비침습성 혈당 모니터링
• AI
• 임상시험의 분석
• 중요 포인트
• 임상시험 분석 : 연구 유형별
• 임상시험 분석 : 상태별
• 임상시험 분석 : 페이즈별
• 특허 분석
• 중요 포인트
• 특허 : 연별
• 특허 : 주요 출원인별
• 특허 : 주요 특허 보유자별
• 특허 : 관할별

제6장 시장 부문 분석

• 세분화 내역
• 세계의 당뇨병 치료제 및 진단 시장 : 제품별
• 중요 포인트
• 당뇨병 치료제
• 당뇨병 모니터링 장비 및 액세서리
• 인슐린 전달 장치
• 세계의 당뇨병 치료제 및 진단 시장 : 최종 사용자별
• 중요 포인트
• 재택 케어 환경
• 병원 및 진료소
• 진단 센터
• 지리적 내역
• 세계의 당뇨병 치료제 및 진단 시장 : 지역별
• 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 중동 및 아프리카
• 남미

제7장 경쟁 정보

• 중요 포인트
• 경쟁 구도
• 주요 기업
• Novo Nordisk A/S
• Lilly
• Abbott
• Dexcom
• Medtronic
• Embecta Corp.
• 주요 전략적 전개

제8장 당뇨병 치료제 및 진단에서의 지속가능성 : ESG의 관점

• ESG : 서문
• 당뇨병 치료제 및 진단에서 ESG
• 주요 ESG 과제
• ESG 성능 분석
• 환경 성능
• 사회적 퍼포먼스
• 거버넌스 퍼포먼스
• BCC Research의 결론

제9장 부록

• 조사 방법
• 출처
• 약어
• 기업 프로파일
• ABBOTT
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• B. BRAUN SE
• DEXCOM INC.
• EMBECTA CORP.
• F. HOFFMANN-LA ROCHE LTD.
• INSULET CORP.
• LIFESCAN IP HOLDINGS LLC.
• LILLY USA LLC.
• MEDTRONIC
• MERCK & CO. INC.
• NOVO NORDISK A/S
• SANOFI
• TERUMO CORP.
• 신흥 스타트업 기업 및 시장 디스랩터

영문목차

The global market for diabetes therapeutics and diagnostics is estimated to grow from $134.9 billion in 2025 to reach $241.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% from 2025 through 2030.

The North American market for diabetes therapeutics and diagnostics is estimated to grow from $54.6 billion in 2025 to reach $99 billion by the end of 2030, at a CAGR of 12.6% from 2025 through 2030.

The Asia-Pacific market for diabetes therapeutics and diagnostics is estimated to grow from $31.6 billion in 2025 to reach $60.9 billion by the end of 2030, at a CAGR of 14% from 2025 through 2030.

Report Scope

The report provides an overview of the global diabetes therapeutics and diagnostics market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025, and projected data for 2026 through 2030.

The market is segmented by product and end-user. The diabetes market by product is divided into three segments: diabetes therapeutics, diabetes monitoring devices and accessories, and insulin delivery devices. Diabetes therapeutics encompass injectable therapies, such as Glucagon-Like Peptide-1 (GLP-1) and insulin, as well as oral antidiabetic drugs (OADs). Diabetes monitoring devices are categorized into blood glucose test strips (BGTS), blood glucose meters, lancets and lancet devices, and continuous glucose monitoring (CGM) systems. Insulin delivery devices are further divided into insulin pumps, insulin pens and needles, insulin syringes, and other products. Based on end users, the market is segmented into hospitals and clinics, home care settings, and diagnostic centers. Geographical regions covered in this study are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., Italy, France, Spain and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, focusing on all the major countries in these regions.

This study further focuses on the driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing the leading global companies in diabetes therapeutics and diagnostics. It also contains a dedicated section of company profiles that covers companies' overviews, key financials, product portfolios and recent developments.

Report Includes

• 161 data tables and 72 additional tables
• In-depth analysis of the global markets for diabetes therapeutics and diagnostics
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by product type, end user and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of various macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analysis
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Abbott, Dexcom, Novo Nordisk A/S, Eli Lilly and Co., and Sanofi

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Technological Advances
• Conclusion

Chapter 2 Market Overview

• Overview
• Epidemiology of Diabetes
• Regional Distribution
• Gender Distribution
• Porter's Five Forces Analysis
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Low to Moderate)
• Bargaining Power of Buyers (High)
• Threat of Substitutes (Low)
• Competition in the Industry (Low to Moderate)
• Macroeconomic Factors Analysis
• Healthcare Spending
• Insurance Coverage and Reimbursement Policies
• Technological Advances
• The U.S. Tariff Scenario

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Increasing Prevalence of Diabetes
• Growing Geriatric Population
• Changing Lifestyle Habits
• Market Restraints
• High Cost of Diabetes Care
• Limited Healthcare Access in Low- and Middle-Income Countries
• Market Opportunities
• Integration of AI, IoT and Wearables for Remote Monitoring
• Government Funding and Initiatives
• Growing Public-Private Partnerships and Industry Collaborations
• Market Challenges
• Data Privacy and Cybersecurity Risks
• Shortage of Skilled Professionals

Chapter 4 Regulatory Landscape

• Regulatory Frameworks
• U.S.
• Europe
• Other Regions

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Next-Generation Insulin Delivery Systems
• Multi-GLP Agonist
• Non-Invasive Glucose Monitoring
• Artificial Intelligence
• Analysis of Clinical Trials
• Key Takeaways
• Analysis of Clinical Trials by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Patent Analysis
• Key Takeaways
• Patents, by Year
• Patents, by Leading Applicant
• Patents, by Leading Patent Holder
• Patents, by Jurisdiction

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Global Diabetes Therapeutics and Diagnostic Market, by Product
• Key Takeaways
• Diabetes Therapeutics
• Diabetes Monitoring Devices and Accessories
• Insulin Delivery Devices
• Global Diabetes Therapeutics and Diagnostic Market, by End User
• Key Takeaways
• Home Care Setting
• Hospitals and Clinics
• Diagnostic Centers
• Geographic Breakdown
• Global Diabetes Therapeutics and Diagnostic Market, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Leading Companies
• Novo Nordisk A/S
• Lilly
• Abbott
• Dexcom
• Medtronic
• Embecta Corp.
• Key Strategic Developments

Chapter 8 Sustainability in the Diabetes Therapeutics and Diagnostics Market: An ESG Perspective

• Introduction to ESG
• ESG in Diabetes Therapeutics and Diagnostics
• Key ESG Issues
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBOTT
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• B. BRAUN SE
• DEXCOM INC.
• EMBECTA CORP.
• F. HOFFMANN-LA ROCHE LTD.
• INSULET CORP.
• LIFESCAN IP HOLDINGS LLC.
• LILLY USA LLC.
• MEDTRONIC
• MERCK & CO. INC.
• NOVO NORDISK A/S
• SANOFI
• TERUMO CORP.
• Few Emerging Start-ups/Market Disruptors